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Cystic fibrosis (CF) patients are highly susceptible to chronic pulmonary disease caused by mucoid Pseudo-
monas aeruginosa strains that overproduce the exopolysaccharide alginate. We showed here that a mutation in
zwf, encoding glucose-6-phosphate dehydrogenase (G6PDH), leads to a90% reduction in alginate production
in the mucoid, CF isolate, P. aeruginosa FRD1. The main regulator of alginate, sigma-22 encoded by algT (algU),
plays a small but demonstrable role in the induction of zwf expression in P. aeruginosa. However, G6PDH
activity and zwf expression were higher in FRD1 strains than in PAO1 strains. In PAO1, zwf expression and
G6PDH activity are known to be subject to catabolite repression by succinate. In contrast, FRD1 zwf expression
and G6PDH activity were shown to be refractory to such catabolite repression. This was apparently not due to
a defect in the catabolite repression control (Crc) protein. Such relaxed control of zwf was found to be common
among several examined CF isolates but was not seen in other strains of clinical and environmental origin. Two
sets of clonal isolates from individual CF patient indicated that the resident P. aeruginosa strain underwent an
adaptive change that deregulated zwf expression. We hypothesized that high-level, unregulated G6PDH activity
provided a survival advantage to P. aeruginosa within the lung environment. Interestingly, zwf expression in
P. aeruginosa was shown to be required for its resistance to human sputum. This study illustrates that
adaptation to the CF pulmonary environment by P. aeruginosa can include altered regulation of basic metabolic
activities, including carbon catabolism.
Pseudomonas aeruginosa is an important opportunistic and
nosocomial bacterial pathogen that contributes to a high rate
of fatality among cystic fibrosis (CF) patients. During patho-
genesis, the CF lung environment promotes and selects for
multiple phenotypic and genotypic alterations in P. aeruginosa
(29). The most obvious and predominant alteration selected
within the CF lung is overproduction of the exopolysaccharide
alginate (7). The appearance of these alginate-overproducing
strains, also known as mucoid variants, correlates with the
establishment of a chronic lung infection and a poor prognosis
for the CF patient (8). The roles for alginate in virulence are
varied and include neutralization of oxygen radicals (38), in-
hibition of phagocytosis (30), inhibition of antibiotic penetra-
tion (10), and inhibition of complement activation (32). Al-
though a significant number of P. aeruginosa isolates from
adult CF patients are mucoid (7), presentations of the mucoid
phenotype in each isolate differ with respect to amount of
alginate produced, stability of the phenotype, and growth con-
ditions that promote alginate production. These variations im-
ply that there are multiple factors that affect alginate produc-
tion, which may be influenced by the CF lung environment.
Given the correlation of alginate overproduction with pulmo-
nary deterioration in CF patients, a better understanding of
alginate regulation and production may suggest strategies for
down-regulating alginate within the CF lung environment (15).
Production of alginate is an energy-costly process that di-
verts carbon sources from being utilized for energy and growth
towards alginate production. The fact that the majority of
P. aeruginosa CF isolates produce copious amount of alginate
suggests that these isolates require alginate production in vivo.
Carbon metabolism and alginate production are intimately
related such that defects in carbon catabolism have dramatic
effects on alginate production (27). Much of our current
knowledge regarding carbon catabolism in P. aeruginosa is
derived from studies with nonmucoid strain PAO1, a wound
isolate, whereas much of our current knowledge of alginate
production is derived from CF isolates like FRD1. In PAO1,
the genes that encode enzymes for the major carbon catabolic
pathway are organized into several operons that comprise the
hexose regulon (hex-regulon). The hex-regulon is induced by
growth on carbon sources such as glucose, gluconate, and gly-
cerol but not by succinate and other intermediates of the tri-
carboxylic acid (TCA) cycle (12, 14). To date, only two regu-
latory proteins that control the hex-regulon in PAO1 have
been identified, and both are repressors: Crc (catabolite re-
pression control) and HexR (2, 42). However, a molecular
mechanism by which Crc mediates catabolite repression in
P. aeruginosa has not yet been elucidated, and the physiological
role of HexR in carbon catabolism is unknown. Moreover,
neither of these regulators, or even carbon metabolism in gen-
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eral, have been extensively investigated in CF isolates of
P. aeruginosa, which are reported to differ extensively from
non-CF isolates in a number of characteristics (4, 6, 9, 16, 17,
22, 43, 48). In this study, a key enzyme of carbon catabolism
and the Entner-Doudoroff pathway, glucose-6-phosphate de-
hydrogenase (G6PDH, or Zwf) was examined in a mucoid CF
isolate because of its potential role in alginate overproduction.
MATERIALS AND METHODS
Bacterial strains, plasmids, and media. Bacterial strains and plasmids used in
this study are listed in Table 1. Unless otherwise indicated, bacteria were grown
in L broth, L broth without NaCl, or L broth supplemented with appropriate
antibiotics at 37°C with aeration. No carbon-E minimal medium (NCE) (5) was
supplemented with 0.1% Casamino Acids and with glycerol (40 mM), succinate
(40 mM), or glycerol and succinate as the carbon source(s). Basal salts medium
was supplemented with succinate (40 mM) and lactamide (20 mM). L agar
without NaCl was supplemented with 8% sucrose for use in negative selection of
sacB. Pseudomonas isolation agar supplemented with appropriate antibiotics was
used to select for P. aeruginosa transconjugants and to counterselect Escherichia
coli. The following amounts of antibiotics were used in this study (per milliliter):
100 g ampicillin for E. coli, 125 g carbenicillin for P. aeruginosa, and 20 and
180 g gentamicin (Gm) for E. coli and P. aeruginosa, respectively.
DNA manipulations, transformations, and conjugations. E. coli strain DH10B
was routinely used as a host strain for cloning. DNA was introduced into E. coli
by electroporation and into P. aeruginosa by conjugation as previously described
(41). Plasmids were purified with QIAprep spin miniprep columns made by
QIAGEN (Valencia, CA). DNA fragments were excised from agarose gels and
purified using the Qiaex II DNA gel extraction system (QIAGEN) according to
the manufacturer’s instructions. Restriction enzymes and DNA modification
enzymes were purchased from New England Biolabs (Beverly, MA). Either Pfu
from Stratagene (La Jolla, CA) or Taq from New England Biolabs was used for
PCR amplification of DNA. Oligonucleotides were purchased from Operon, Inc.
(Alameda, CA), or Integrated DNA Technologies, Inc. (Coralville, IA).
Construction of zwf and crc mutants. Derivatives of FRD1 and PAO1 with a
mutation in zwf were constructed as follows: a 1.55-kb fragment containing zwf
was PCR amplified from FRD1 with Pfu, digested with EcoRI and XbaI and then
cloned into pBluescript K() between the EcoRI-XbaI sites. A gentamicin
resistance cassette isolated from pUCGM1 (35) as a BamHI fragment was then
cloned into the internal BamHI site within zwf to disrupt the open reading frame
(ORF). Next, an origin of transfer (oriT) from pLS217 was added as an EcoRI
TABLE 1. Bacterial strains and plasmidsa
Strain(s) or plasmid Genotype, relevant characteristics Source
Strains
FRD1 CF isolate, mucoid, rough phenotype 28
PAO1 Wound isolate, nonmucoid 11
PDO300 PAO1mucA22, mucoid 24
PAO1zwf (LS637) PAO1zwf101::aacCI This study
PAO1crc (LS1441) PAO1crc101 This study
FRD1crc (LS1439) FRD1crc101 This study
FRD1zwf (LS636) FRD1zwf101::aacCI This study
FRD1algD (FRD1131) FRD1algD::Tn501, nonmucoid 1
FRD1algT (LS586) FRD1 algT101::aacCI, polar, nonmucoid 37
FRD1zwf (LS974) FRD1zwf complemented for zwf in trans This study
PAO1zwf (LS637) PAO1zwf complemented for zwf in trans This study
FRD1zwf (LS1518) FRD1zwf complemented for zwf in cis This study
PAO1zwf (LS1520) PAO1zwf complemented for zwf in cis This study
FRD1crc (LS1447) FRD1crc complemented for crc This study
PAO1crc (LS1448) PAO1crc complemented for crc This study
DO5 and DO249 CF isolates, mucoid This study
DO60 CF isolate, nonmucoid 37
DO62 CF isolate, nonmucoid This study
DO133 and DO326 CF isolate, mucoid 37
P1 and P2 Blood isolates, nonmucoid This study
P15 and P16 Peritoneal fluid isolates, nonmucoid This study
PA14 Wound isolate, nonmucoid 33
3064 CF isolate, mucoid 47
PAM57-15 and PA2192 CF isolate, mucoid 44
ENV2, ENV8, and ENV10 Garden vegetable isolates, nonmucoid 22
ENV46, ENV48, and ENV54 River isolates, nonmucoid 22
CF09-CF40 CF isolates, patients 12, 13 and 17 21, this study
PA2192zwf PA2192 zwf101::aacCI This study
Plasmids
pEX100T Cloning vector with sacB 36
pLS214 pUC19 with moriT at HindIII 40
pLS217 pUC18 with moriT at EcoRI 40
pLS594 zwf-lacZ transcriptional fusion in pSS223 This study
pLS1436 crc101 in pEX100T This study
pLS1446 crc complementing plasmid This study
pLS1051 crc-lacZ translational fusion in pSS361 This study
pSS223 lacZ operon fusion vector 47
pSS366 zwf complementing plasmid, trans This study
pLS1517 zwf complementing plasmid, cis This study
pUCGM1 ColE1 Ampr Gmr 35
pLS1155 Regulatable promoter/repressor system This study
pLS1393 Regulatable crc upon plasmid integration This study
a Abbreviations used for genetic markers are described by Holloway et al. (11). Apr, ampicillin resistance. Alternate strain names are shown in parentheses.
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fragment. The final construct, pLS635, was conjugated into FRD1 and PAO1,
and potential zwf mutants were isolated as gentamicin-resistant (Gmr) and
carbenicillin-sensitive colonies. The presence of the mutant allele and the ab-
sence of the wild-type allele were verified by PCR analysis. To complement the
zwf mutation in trans, zwf was PCR amplified with Pfu and cloned into the
P. aeruginosa-E. coli shuttle vector, pUCP19, as a 1,850-bp EcoRI-HindIII frag-
ment. The resulting plasmid, pSS354, was converted into a mobilizable plasmid,
pSS366, by the addition of a moriT (40) of plasmid RP4. To complement the zwf
mutation in cis, zwf was PCR amplified with Pfu and cloned into pBK as a
2,380-bp EcoRI-SmaI fragment. The resulting plasmid, pLS1515, was converted
to a mobilizable plasmid, pLS1517, by the addition of a mini-oriT (moriT) to the
HindIII site. pSS366 and pLS1517 were introduced into P. aeruginosa via tripa-
rental mating. To construct a crc mutant in P. aeruginosa, an internal 343-bp
fragment was deleted from the crc coding region by using the splicing by overlap
extension technique (SOEing) (45). First, an 820-bp fragment, 5 to and con-
taining the first 180 bp of the crc ORF, was PCR amplified from FRD1 with Pfu.
Concurrently, a 999-bp fragment, 3 to and containing the last 255 bp of the crc
ORF was PCR amplified with Pfu. The two fragments shared approximately 20
bp of overlap so that they could be joined by SOE PCR. In the second round of
PCR amplification, the fragments described above served as DNA templates by
use of the 5 primer of the first fragment and the 3 primer of the second
fragment to generate a 1,819-bp product. This product, with 343 bp deleted from
the crc coding sequence, was cloned into pEX100T, which carries a carbenicillin
resistance gene and a counterselectable marker, sacB (36), to generate pLS1436.
Following the conjugation of pLS1436 into P. aeruginosa, merodiploid colonies
with the plasmid integrated into the P. aeruginosa chromosome via homologous
recombination were selected for their resistance to carbenicillin. The merodip-
loids were subsequently resolved by selecting for growth on medium containing
sucrose to promote the loss of plasmid DNA sequences carrying sacB. This
resulted in allelic exchange between the wild-type crc and crc alleles. The
presence of the mutant allele and the loss of plasmid and the wild-type copy of
crc in the putative crc mutants were verified by PCR. To complement the crc
mutation, the crc coding sequence, along with approximately 800 bp of upstream
sequence and 80 bp of downstream sequence, was PCR amplified from FRD1 by
using Pfu and cloned into pUCP19 as a BamHI-EcoRI fragment. A moriT
isolated from pLS214 was then cloned as a HindIII fragment to generate
pLS1446 and the plasmid was introduced into P. aeruginosa crc mutants via
conjugation. The complemented FRD1crc and PAO1crc mutants were desig-
nated FRD1crc (LS1447) and PAO1crc (LS1448), respectively.
Construction of transcriptional and translational fusions. To construct the
zwf::lacZ and crc::lacZ fusions, DNA fragments containing the promoter for the
genes and a portion of the 5 coding sequence were PCR amplified from FRD1
genome using Pfu DNA polymerase, digested with the appropriate enzymes and
cloned into either pSS223 for a transcriptional fusion (zwf::lacZ) or pSS361 for
a translational fusion (crc::lacZ). pSS361 is a mobilizable lacZ translational
fusion vector that can replicate in P. aeruginosa (40). All plasmid constructs were
verified by PCR analysis and restriction digestion before they were conjugated
into P. aeruginosa.
Biochemical assays. Alginate was isolated from P. aeruginosa culture super-
natants that were dialyzed against distilled water as previously described (41),
and alginate (i.e., uronic acid) level was quantified by the carbazole method (13)
using Macrocystis pyrifera alginate (Sigma) as a standard. G6PDH activity was
determined as described previously (18), and -galactosidase assays were pre-
formed as described by Miller (25). Pyocyanin was quantified from 20-h cultures
as previously described (3). Amidase activity was determined as previously de-
scribed (20).
RAPD analysis of CF isolates. CF isolates 132 to 137 were previously typed by
Mahenthiralingam et al. (21). To type CF 139 and 140, random amplified poly-
morphic DNA (RAPD) analysis of these isolates by using primer 208 (ACG
GCCGACC) was conducted as previously described, and the results were com-
pared to RAPD analysis of CF isolates 132 to 137 with the same primer.
Sputum inhibition assay. NCE agar plates supplemented with 20 mM glycerol
were seeded with 5 l of an overnight culture of P. aeruginosa diluted into 100 l
of saline. A 5-l drop of sputum (1.3 g/ml protein) was placed in the center of
the plate and the plates were incubated overnight at 32°C.
Oxidative stress assays. Overnight bacterial cultures were adjusted to an
optical density at 600 (OD600) of 2.0; 5 l was inoculated into 1 ml fresh L
broth (minus NaCl for paraquat assays) containing increasing concentrations of
paraquat or hydrogen peroxide as described by Ma et al. (18). The samples were
incubated for 20 h at 37°C with aeration after which the final OD600 was
recorded.
DNA sequencing and statistical analysis. The PCR amplified crc gene from
FRD1 (carried on pLS1334) was sequenced by The Auburn University Research
and Instrumentation Facility (Auburn University, AL.). Statistical analysis was
performed using In Stat (GraphPad software, San Diego, CA).
RESULTS
G6PDH promotes alginate production. Glucose-6-phos-
phate dehydrogenase is encoded by zwf and converts glucose-
6-phosphate to 6-phosphogluconate; it is the first enzyme in
the Entner-Doudoroff pathway, which is central to carbon me-
tabolism in Pseudomonas sp. We constructed a zwf::aacCI
(Gmr) insertion mutant in the CF mucoid isolate, P. aeruginosa
FRD1, as a starting point to elucidate the relationship between
carbon catabolism and alginate production in CF strains. Cell
extracts of FRD1 in L broth logarithmic culture contained
105 mIU of G6PDH, whereas, the FRD1zwf mutant con-
tained no detectable G6PDH activity. FRD1 produced 675 
42 g/ml of alginate, whereas FRD1zwf produced 75 
8.25 g/ml of alginate, or 11% compared to the wild-type
mucoid strain. This defect in alginate production levels was
fully complemented (780  89.7 g/ml) by wild-type zwf on
plasmid pSS366. Thus, the flux of carbon via G6PDH is im-
portant for high-level alginate production in mucoid P. aerugi-
nosa FRD1.
Effect of alginate production on G6PDH activity. Since
G6PDH is required for high-level alginate production in
FRD1, we hypothesized that mucoid strains might possess
higher levels of G6PDH activity than nonmucoid strains. Mu-
coid conversion usually occurs as a result of a mutation in an
anti-sigma factor encoded by mucA (23), which leads to the
activation (i.e., deregulation) of sigma-22, which is also known
as AlgT or AlgU. This alternative extracytoplasmic-function
sigma factor is at the top of a hierarchy of regulators for
alginate biosynthesis (49). However, mucoid FRD1 (with a
mucA22 allele) contained G6PDH levels that were only about
30% higher than those of the nonmucoid FRD1algT mutant
when grown in L broth (P  0.001) (Fig. 1). To test whether
disruption of the alginate biosynthesis pathway affected
G6PDH activity, an FRD1algD nonmucoid mutant was also
tested. However, a mutation in algD, the first gene in the
alginate biosynthetic operon (1), did not significantly affect
G6PDH activity (P 	 0.05) in FRD1. As described above, the
FRD1zwf mutant contained no G6PDH activity. Thus, there
was only a minor correlation between alginate overproduction
and G6PDH levels by comparing these FRD1 derivatives. The
G6PDH activities of the nonmucoid non-CF isolate, PAO1,
and its mucoid mucA22 mutant derivative, PDO300, were also
compared. PDO300 displayed a slightly higher level of G6PDH
activity than its nonmucoid parent, PAO1 (P  0.01) (Fig. 1).
However, it was striking that the FRD1 derivatives contained
about 10-fold more G6PDH activity than the PAO1 derivatives
when grown in L broth (Fig. 1). This suggested that FRD1,
which had undergone adaptation to the CF pulmonary envi-
ronment, may have undergone a genetic change that up-regu-
lated G6PDH activity.
Catabolite repression of zwf transcription. To study the
transcriptional control of zwf, a zwf-lacZ transcriptional fusion
was constructed and designated pLS594. The results showed
that L broth-grown P. aeruginosa strains expressed zwf-lacZ in
a manner that closely mimicked the G6PDH activity patterns
described above. Mucoid FRD1 contained approximately 40%
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more zwf-lacZ transcriptional activity than nonmucoid FRDalgT
(Fig. 2). Mucoid PDO300 contained about 40% more zwf-lacZ
transcriptional activity than nonmucoid PAO1 (Fig. 2). Thus,
alginate production correlated with a moderate increase in zwf
expression. However, a marked increase in zwf-lacZ transcrip-
tional activity was observed for FRD1 strains compared to
PAO1 strains grown in L broth. This was similar to that de-
scribed above with G6PDH levels.
We next used the zwf-lacZ fusion to examine its regulation in
the PAO and FRD strain backgrounds. Previous studies on
PAO1 (grown in defined minimal media) have shown that zwf
expression is high when using the carbon source glycerol, glu-
cose, or gluconate; glycerol elicits the highest response. The
presence of a TCA cycle intermediate, such as succinate, re-
duces zwf expression via catabolite repression (18). Similar
studies of carbon source utilization by CF isolates of P. aerugi-
nosa have not been reported and so were examined here.
Although PAO1 grew well in minimal media, FRD1 and other
CF isolates grew slowly, and so 0.1% Casamino Acids were
added to all defined media to permit robust growth. CF iso-
lates may be partially deficient in the synthesis of one or more
essential nutrients, which has been previously observed (43).
Expression of zwf-lacZ in PAO1 was approximately ninefold
higher with glycerol than with succinate (Fig. 2), which was in
agreement with previous studies on catabolite repression in
this strain (19). Mucoid PDO300 (a mucA22 derivative of
PAO1) contained approximately 1.5-fold more zwf-lacZ activ-
ity than the parent when grown on glycerol but still showed
strong catabolite repression of zwf-lacZ with succinate (Fig. 2).
In contrast, zwf-lacZ expression in FRD1 was two- to fourfold
higher than in the PAO strains with glycerol, and strong re-
pression of zwf-lacZ by succinate was not observed (Fig. 2).
Overall, the activation of sigma-22 activity in P. aeruginosa
produced a minor enhancement of zwf-lacZ within a strain
background. However, the catabolite control of zwf was re-
laxed in the CF strain, FRD1, and its derivatives. This was a
phenotype much like a crc mutant (46).
Role of Crc in PAO1 and FRD1. P. aeruginosa PAO1 is
known to preferentially metabolize organic acids and TCA
cycle intermediates, such as succinate, before metabolizing
nonorganic acids, such as glycerol, or glucose (2). Further-
more, expression of zwf and other genes involved in catabolism
of hexoses are repressed in the presence of preferred carbon
sources in PAO1 (18). Catabolite repression of zwf in PAO1 is
mediated by the catabolite repression control protein (Crc)
(46) and at the transcriptional level (19), although the mech-
anism has not been deduced.
To address the role of Crc in FRD1, we constructed crc
mutants of FRD1 and PAO1 (see Materials and Methods).
The FRD1crc and PAO1crc mutants overproduced a blue pig-
ment on agar plates and in liquid culture, which has been
observed previously with other crc mutants (31). This blue
coloration appears to be due to the overproduction of pyocy-
anin (data not shown). This phenotype was complemented by
crc in trans on plasmid pLS1446. We compared G6PDH activ-
ities of the wild type and the crc mutant when the bacteria were
grown in the presence of succinate (preferred carbon source),
glycerol (nonpreferred carbon source), or a combination of
succinate and glycerol. In agreement with published results,
the level of G6PDH activity was high in PAO1 with glycerol
and was repressed by succinate plus glycerol (Fig. 3A). As
previously described (46), this catabolite repression of Zwf
required Crc because G6PDH activity was not severely re-
pressed in the PAO1crc mutant by succinate plus glycerol in
PAO1 (Fig. 3A).
In contrast, there was little phenotypic difference between
FRD1 and FRD1crc. G6PDH remained high in the presence
of succinate plus glycerol in both strains, as if parent strain
FRD1 lacked a functional Crc control mechanism (Fig. 3B).
Also, G6PDH remained relatively high in both FRD1 and
FIG. 1. G6PDH activity in FRD1, PAO1 and their derivatives.
G6PDH activity was measured from cells grown to an OD600 of approx-
imately 1.0 in L broth. G6PDH activity was normalized to protein con-
centrations, calculated for mIU, and one hundred percent assigned to the
activity observed for FRD1 (105 mIU). The data represent the averages
(standard deviations) of two independent experiments conducted in
duplicate. Alginate production (/–) is shown below the graph.
FIG. 2. Expression of zwf-lacZ in PAO1, FRD1, and their deriva-
tives. A. Cells were grown in with aeration at 32°C in L broth, NCE
plus glycerol or NCE plus succinate as the main carbon source. Sam-
ples were taken at OD600 1.0 and -galactosidase activities (Miller
units) were determined. The data represent the averages (standard
deviations) of three experiments.
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FRD1crc when grown with succinate alone, which strongly
represses zwf transcription in PAO1. Because Crc-mediated
control of G6PDH activity appeared to be defective in FRD1,
we tested for catabolite repression control of amidase. Ami-
dase activity is derepressed in PAO1crc compared to PAO1
when grown in the presence of succinate (preferred substrate)
and lactamide (inducing substrate) (Fig. 4) (20). Although we
observed slightly higher amidase activity in FRD1 compared to
PAO1, we also observed that loss of Crc in FRD1 led to
increased amidase activity. Therefore, deregulation of G6PDH
activity in FRD1 appears to be independent of Crc regulation
when FRD1 is grown in L broth. To determine whether Crc
may be altered in FRD1, a crc-lacZ fusion was constructed
(pLS1051), but little difference in the expression levels was
observed in FRD1 and PAO1 in L broth over time (data not
shown). We then cloned the FRD crc gene and sequenced it
from 400 bp upstream to 80 bp downstream of the crc ORF.
However, the sequence analysis revealed only two conserved
changes compared to crc from PAO1, which did not change
any amino acids, and these were located at nucleotides 606 (C
to T) and 684 (A to G) in the coding sequence. This suggests
that expression of crc in FRD1 is not defective. Studies to
identify the molecular mechanism for this apparent deregula-
tion of zwf in FRD1 are in progress.
High-level G6PDH activity correlates with adaptation to the
CF lung. We next looked at a collection of CF isolates of
P. aeruginosa to see if a high level of expression of zwf in the
presence of succinate (i.e., zwf deregulation) was a common
trait among such strains. We compared G6PDH activity fol-
lowing growth with succinate as a sole carbon source in a
variety of P. aeruginosa isolates: 10 CF isolates, 5 non-CF
clinical isolates, and 6 environmental isolates. Like FRD1, half
of the CF isolates exhibited a high level of G6PDH activity
(defined as 	35 mIU/mg of protein). None of the other 5
clinical or 6 environmental strains exhibited this alteration in
zwf control (Fig. 5). In that 8 of the 10 CF isolates tested were
mucoid but not all of the mucoid isolates had high G6PDH
activity, this small survey suggests that a high level of unregu-
lated G6PDH activity is a trait acquired separately from over-
production of alginate.
We also examined alginate production by mucoid CF strain
PA2192, which retained the normal catabolite repression phe-
notype of zwf when grown in succinate (Fig. 5, lane 6). It
accumulated 835  125 g alginate/ml in an L broth culture,
which is comparable to FRD1. A PA2192zwf mutant was also
constructed, and it accumulated much-reduced levels of algi-
nate (125  25 g/ml), much like an FRD1zwf mutant. Thus,
zwf was required for high-level alginate production in both
classes of CF strains. Also, normally regulated G6PDH activity
can still support substantial alginate production, at least under
laboratory conditions. This led us to consider the possibility
that deregulated G6PDH could have other selective advan-
FIG. 3. Effect of a crc mutation in PAO1 and FRD1 on G6PDH
production. G6PDH activity was measured from cells grown to an
OD600 of approximately 1.0 in NCE supplemented with the indicated
carbon source(s). The data represent the averages (standard devia-
tions) of three experiments.
FIG. 4. Effect of a crc mutation in PAO1 and FRD1 on amidase.
Amidase activity was measured from cells grown to an OD600 of ap-
proximately 1.0 in basal salts medium supplemented with 40 mM
succinate plus 20 mM lactamide. The data represent the averages
(standard deviations) of two independent experiments conducted in
duplicate.
FIG. 5. Survey of G6DPH activity in P. aeruginosa isolates. G6PDH
activity was measured from cells grown to an OD600 of approximately
1.0 in NCE plus succinate. G6PDH activity was normalized to protein
concentrations and calculated for mIU. The data represent the aver-
ages (standard deviation) of two experiments. The asterisks indicate
nonmucoid CF isolates. Lanes: 1, FRD1; 2, 3064; 3, DO5; 4,DO62; 5,
PAM57-15; 6, PA2192; 7, DO326; 8, DO133; 9, DO249; 10, DO60; 11,
P2; 12, P15; 13, P16; 14, P1; 15, PAO1; 16, PA14; 17, ENV2; 18, ENV8;
19, ENV10; 20, ENV46; 21, ENV48; 22, ENV54.
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tages (besides alginate production) for P. aeruginosa while
growing within the CF lung.
G6PDH activity in sequential CF clonal isolates shows se-
lection in vivo for unregulated zwf. Three sets of sequential
P. aeruginosa isolates that had been collected from individual
CF patients were obtained (21). RAPD analysis of these iso-
lates indicates that the isolates are clonal from each patient but
different between patients (data not shown). We observed that
all of the isolates recovered from patient 13 retained low levels
of G6PDH activity throughout the infection (Fig. 6). In con-
trast, the early isolates from patients 12 and 17 displayed low
levels of G6PDH activity, while the later isolates displayed high
levels of G6PDH activity, suggesting a conversion in vivo to the
higher production of G6PDH. From patient 12, we observed a
moderate increase in G6PDH activity between the ages of 8
and 9.6 years, while from patient 17, we observed a 5-fold
increase between the ages of 3.2 and 5. In both patient 12 and
patient 17, the levels of G6PDH activity remained high in
isolates from subsequent years (Fig. 6) following the conver-
sion. Interestingly, in both patients 12 and 17 the conversion to
high levels of G6PDH activity may have preceded the conver-
sion to a dominantly mucoid phenotype, suggesting that in-
creased G6PDH confers some selective advantage to these
isolates within the CF lung.
A defect in zwf causes sputum sensitivity. Previous studies
suggest an association between G6PDH and alginate in pro-
tecting P. aeruginosa from oxidative stress (18, 38). However, in
this study, FRD1 and FRD1zwf showed equal sensitivity to
paraquat and hydrogen peroxide (data not shown). In that the
FRD1zwf mutant was partially defective for alginate produc-
tion, this suggests that neither excess alginate nor G6PDH
activity contributed to increased resistance to oxidative stress
in FRD1 under these laboratory-tested conditions.
In an attempt to explore the selection for high-level G6PDH
activity in P. aeruginosa while in the CF lung environment, we
tested the effect of lung sputum on the growth of several
P. aeruginosa isolates. We observed that lung sputum, either
isolated from CF or non-CF individuals, inhibited the growth
of FRD1zwf and PAO1zwf mutants but not the parental strains
(Fig. 7). Complementation of zwf in cis restored the ability of
PAO1 and FRD1 to grow in the presence of sputum (data not
shown). The inhibitory effect appeared to be specifically asso-
ciated with loss of zwf, in that a variety of other FRD1 mutants
were not inhibited by sputum, including algT, algD, and crc
mutants (data not shown). In that G6PDH appears to be re-
quired for maximum protection from lung sputum, it is plau-
sible that the selection for deregulated high-level G6PDH ac-
tivity in the CF lung may be associated with the phenomenon.
Identification of the specific inhibitor in sputum or whether
growth on sputum leads to a build up of a toxic intermediate
within the zwf mutants is currently under investigation.
DISCUSSION
The Entner-Doudoroff pathway is an alternative to the
Emden-Meyerhof glycolytic pathway in a diverse group of bac-
teria, including Pseudomonas sp., and it provides both energy
and metabolic precursors for many biosynthetic processes.
Here, we established that a mutation in zwf (encoding G6PDH,
the first enzyme of the Entner-Doudoroff pathway) leads to a
90% reduction in alginate production in the mucoid, CF
isolate of P. aeruginosa, FRD1. This effect was presumably due
to a reduction in the pool of fructose-6-phosphate, the primary
precursor of alginate. Consistent with this model is the obser-
vation that there were no differences between FRD1 and
FIG. 6. Comparison of sequential isolates for unregulated G6PDH
activity. G6PDH activity was measured from cells grown to an OD600
of approximately 1.0 in LB. The data represent the averages (stan-
dard deviations) of two independent experiments conducted in dupli-
cate. The approximate ages of the patients from which the isolates
were collected are shown beneath the graph. The mucoid phenotypes
of the isolates as observed on agar plates are shown.
FIG. 7. Effect of sputum on the growth of P. aeruginosa. NCE agar
plates were seeded with P. aeruginosa and centrally inoculated with
sputum. Shown is growth of the bacteria following an overnight incu-
bation at 32°C.
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FRD1zwf for expression on an algD-lacZ transcriptional fusion
over a growth cycle (data not shown). Mucoid strains produce
large amounts of alginate, which is expensive in terms of car-
bon and energy, and so we began to explore the possibility that
mucoid strains contain increased levels of G6PDH to supply
sufficient amounts of precursor for the alginate pathway. How-
ever, an algD mutation in FRD1, which blocked the biosyn-
thetic pathway for alginate, did not significantly affect G6PDH
levels, indicating that this drain on the pool of metabolic sugar
precursors did not affect G6PDH levels. Also examined was a
FRD1 derivative with a mutation in algT, encoding sigma-22,
the master regulator of alginate biosynthesis, and this defect
did reduce G6PDH by 30%. Also tested was the effect of a
mucA mutation in strain PAO1, which inactivated the anti-
sigma factor of sigma-22 to increase the level of active sig-
ma-22 in the cell and results in alginate gene activation. A
modest increase in G6PDH activity was observed in mucoid
PAO1mucA compared to the wild type. Thus, sigma-22 appar-
ently has a small role in the induction of zwf expression in
P. aeruginosa, which is likely to be indirect because no obvious
sigma-22 consensus sequence could be identified upstream of
the zwf coding region.
The striking observation from the data described above was
that the levels of G6PDH activity and zwf expression were both
severalfold higher in FRD1 than in PAO1 background strains
when grown in L broth. Although caution is always advised when
making interstrain comparisons, this led us to examine whether
zwf in strain FRD1 was still subject to catabolite repression as it
is in PAO1. As expected for PAO1, levels of zwf expression and
G6PDH activity were high following growth with glycerol but low
with succinate or glycerol plus succinate, as previously described
(46). However, in FRD1, levels of zwf expression and G6PDH
activity remained high with succinate or glycerol plus succinate,
suggesting that zwf expression was possibly deregulated and con-
stitutively expressed. Although a mutation affecting Crc or its
expression would produce these phenotypes (46), no evidence
could be found here to support a Crc defect in FRD1. However,
we cannot rule out the possibility that Crc activity is modulated in
P. aeruginosa as it is in Pseudomonas putida (34). Future studies
have been initiated to characterize Crc in FRD1 and other CF
isolates of P. aeruginosa.
Unexpectedly, we found that relaxed control of zwf was not
unique to FRD1 but was actually common to CF isolates.
Among the 10 CF isolates tested, 5 showed high G6PDH when
grown with succinate as the major carbon source. In contrast,
all of the other five clinical or six environmental isolates
showed normal catabolite repression of G6PDH with succi-
nate. Although the sample of strains was small, the results
clearly suggest that adaptation to the CF lung environment
selects for a defect in the repression of zwf expression and may
extend to other genes as well. Fortuitously, several sets of
clonal isolates that had been collected from individual CF
patients over a number of years were available (21). Analysis of
these isolates showed that in two of three patients, the resident
P. aeruginosa strain underwent an adaptation to promote de-
regulated zwf expression. Thus, we hypothesized that a high
level of G6PDH activity provides a survival advantage to
P. aeruginosa within the lung environment because deregulated
zwf variants predominate and persist in vivo following conver-
sion. This is similar to the mucoid phenotype of P. aeruginosa,
which usually arises in the CF lung by adaptive mutation in
mucA, although its predominance is not always immediate
upon conversion (21, 39).
Based on in vitro data shown here, zwf expression in
P. aeruginosa is required for resistance to human sputum. A
simple plate test was developed which dramatically showed
that G6PDH was necessary in both the FRD1 and PAO1 strain
backgrounds to prevent growth inhibition. Thus, up-regulation
of zwf may protect P. aeruginosa within the CF lung from some
factor found in human sputum. The FRD1zwf did not become
hypersensitive to paraquat or hydrogen peroxide, suggesting
that the selection for increased G6PDH activity in CF isolates
was not related to oxidative stress resistance. Also, nonmucoid
FRD1algT and FRD1algD mutants did not show increased
sensitivity to CF sputum, so reduced alginate levels associated
with zwf mutation were not associated with sputum sensitivity.
Alternatively, a substance in sputum may cause the accumula-
tion of a toxic intermediate in the zwf mutants. Future studies
will attempt to identify the substance in sputum that produced
this phenotype.
The list of reported differences between CF isolates and
other clinical isolates of P. aeruginosa is rapidly expanding.
Within the CF lung, P. aeruginosa acquires multiple phenotypic
and genotypic changes, including alterations and attenuation
of several virulence factors, such as reduced ADP-ribosylating
activity of exotoxin A, loss of motility, loss of O antigen in
lipopolysaccharide, increased auxotrophy, antibiotic resistance,
defects in type III secretion, and reduced production of pro-
teases and phospholipase C (4, 6, 9, 16, 17, 22, 26, 43, 48).
Furthermore, CF isolates of P. aeruginosa appear to utilize a
different set of virulence determinants and pathogenic mech-
anisms to cause disease than non-CF isolates (37). Presumably,
the hostile environment of the CF lung not only induces mu-
tations in P. aeruginosa but also selects those mutants best able
to survive and persist. Therefore, it is not unreasonable to
expect that basic metabolic activities, such as regulation of
carbon catabolism, might also be altered in CF isolates of
P. aeruginosa, as demonstrated in this study. However, because
basic metabolic processes and not just virulence determinants
are altered in CF P. aeruginosa, these isolates may respond
differently than non-CF isolates to treatments that were devel-
oped for non-CF isolates. Thus, in order to develop more
effective treatments for pulmonary infections in CF patients, it
is important to further characterize the physiology and metab-
olism of CF isolates of P. aeruginosa.
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